Polysaccharide Iron Complex
Active ingredient
Sold as NIFEREX ELIXIR
- Drug class
- -
- Availability
- See label
- Markets covered
- 1
- Products on record
- 1
Overview
Polysaccharide Iron Complex is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 1 | September 5, 2025 |
GBUnited Kingdom· MHRA
1 product
Uses
For the prophylaxis and treatment of uncomplicated iron deficiency anaemia.
How to take
Posology Niferex Elixir 30 ml paediatric dropper bottle should not be used in infants older than 6 months of age. For children older than 6 months, the 190ml Niferex Elixir should be used for dosing. 4 mg of polysaccharide-iron complex equivalent to 100mg of elemental iron.
4): Group Dose of elemental iron Given in 2-3 divided dose Low birth weight babies who are solely breast fed 5 mg/day Higher doses up to 2mg/kg/day might be needed to cover the needs of growing exclusively breastfed infants. 200mg) of elemental iron in 2-3 divided doses.
Elderly Patients:
The normal adult dose is appropriate. Pregnancy (during second and third trimester): 5ml daily (100mg elemental iron daily). Method of administration For oral use.
This is not medical advice. Consult a qualified healthcare professional.
Side effects & warnings
Anorexia, nausea, vomiting, gastro-intestinal discomfort, constipation, diarrhoea, dark stools and allergic reactions. These side-effects may be minimised by taking the elixir after food. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.
Patients post-gastrectomy have poor absorption of iron. Caution is advised when prescribing iron preparations to individuals with history of peptic ulcer. Duration of treatment should generally not exceed 3 months after correction of anaemia.
Co-existing deficiency of vitamin B12 or folic acid should be ruled out since combined deficiencies produce microcytic blood film. Iron deficiency in a male patient warrants careful investigation to determine its cause which forms the basis of primary treatment.
Patients suffering from iron overload are particularly susceptible to infection. Treatment of iron overload should be with caution.
The label will state:
Important warning: Contains Iron. Keep out of the sight and reach of children, as overdose may be fatal. This will appear on the front of the pack within a rectangle in which there is no other information.
This is not medical advice. Consult a qualified healthcare professional.
Who should not take it
1 - Known iron overload. - Haemosiderosis and haemochromatosis. - Active peptic ulcer. - Repeated blood transfusion. - Regional enteritis and ulcerative colitis. - Haemolytic anaemias.
This is not medical advice. Consult a qualified healthcare professional.
Brands in United Kingdom (1)
Sources & citations
- [1]MHRA (UK) · PL113110023 · revised September 5, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.